TY - JOUR

T1 - Rationaler for behandling med januskinase 1/2-hæmning af svært syge patienter med COVID-19-pneumoni

AU - Hasselbalch, Hans Carl

AU - Poulsen, Anne

AU - Skov, Vibe

AU - Kjær, Lasse

AU - Nielsen, Claus Henrik

AU - Poulsen, Troesl Dirch

PY - 2020

Y1 - 2020

N2 - Severely afflicted patients with the COVID-19 may become in need of mechanical ventilation. The cause of acute respiratory failure is a massive hyperinflammation in the lungs, and treatment with glucocorticoids is not recommended by the WHO. A rare haematological disease, the virus-associated haemophagocytic lymphohistiocytosis syndrome (HLS), is associated with high mortality and a similar hyperinflammation syndrome. Janus kinase (JAK) 1/2 inhibitor treatment is highly efficacious in HLS. In this review, we discuss the rationales and perspectives for using JAK1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia.

AB - Severely afflicted patients with the COVID-19 may become in need of mechanical ventilation. The cause of acute respiratory failure is a massive hyperinflammation in the lungs, and treatment with glucocorticoids is not recommended by the WHO. A rare haematological disease, the virus-associated haemophagocytic lymphohistiocytosis syndrome (HLS), is associated with high mortality and a similar hyperinflammation syndrome. Janus kinase (JAK) 1/2 inhibitor treatment is highly efficacious in HLS. In this review, we discuss the rationales and perspectives for using JAK1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia.

KW - Betacoronavirus

KW - COVID-19

KW - Coronavirus Infections/drug therapy

KW - Humans

KW - Janus Kinase Inhibitors/therapeutic use

KW - Lymphohistiocytosis, Hemophagocytic/drug therapy

KW - Pandemics

KW - Pneumonia, Viral/drug therapy

KW - SARS-CoV-2

M3 - Review

C2 - 32584762

VL - 182

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 25

M1 - V04200234

ER -